313 results on '"Drescher, Charles W."'
Search Results
2. False-Positive Screening Events and Worry Influence Decisions About Surgery Among High-Risk Women
3. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials
4. Identifying post-menopausal women at elevated risk for epithelial ovarian cancer
5. Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass
6. Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women
7. Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells
8. Figure S2 from Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer
9. Supplementary Figure Legends from Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer
10. Data from Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer
11. Supplementary Tables from Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer
12. Supplementary Figure 2 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
13. Supplementary Table 2 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
14. Supplementary Figure 1 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
15. Supplementary Table 1 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
16. Supplementary Table 3 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
17. Supplementary Figure 3 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
18. Data from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
19. Supplementary Table 6 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
20. Supplementary Methods from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
21. Supplementary Table 5 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
22. Supplementary Table 4 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
23. Supplementary Figure 4 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
24. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study
25. Supplementary Data from Prophylactic In Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models
26. Supplementary Materials from Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials
27. Data from Prophylactic In Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models
28. Supplementary Appendix from Ultrasound Molecular Imaging in a Human CD276 Expression–Modulated Murine Ovarian Cancer Model
29. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors
30. 28 Factors impacting genomic testing rates among epithelial ovarian cancer patients across a large community-based healthcare system
31. 54 Patterns of genomic testing for epithelial ovarian cancer across a large community-based health care network – a real world experience
32. Assessment of quality improvement priorities to improve care delivery for patients with ovarian cancer.
33. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
34. Involvement in decision-making about treatment and ovarian cancer survivor quality of life
35. Circulating microRNAs as Stable Blood-Based Markers for Cancer Detection
36. Cancer case trends following the onset of the COVID‐19 pandemic: A community‐based observational study with extended follow‐up
37. Making Decisions about Screening for Ovarian Cancer
38. Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
39. Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases
40. High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer
41. Robotic surgery in gynecologic oncology: program initiation and outcomes after the first year with comparison with laparotomy for endometrial cancer staging
42. Biomarkers and Strategies for Early Detection of Ovarian Cancer
43. Cancer case trends following the onset of the COVID‐19 pandemic: A community‐based observational study with extended follow‐up.
44. The Effect of Regular Exercise and Yoga on Health-Related Quality of Life Among Ovarian Cancer Survivors
45. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription
46. Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer
47. Prophylactic In Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models
48. 53 Frequency of homologous recombination deficiency in a large community-based cohort of epithelial ovarian cancer cases
49. Development of An Ovarian Cancer Symptom Index: Possibilities for earlier detection
50. Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.